Format

Send to

Choose Destination
Orphanet J Rare Dis. 2014 Nov 15;9:161. doi: 10.1186/s13023-014-0161-1.

Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy.

Author information

1
Division of Metabolic Diseases and Children's Research Center, University Children's Hospital Zürich, Zürich, Switzerland. martina.huemer@kispi.uzh.ch.
2
Radiz - Rare Disease Initiative Zürich, University Zürich, Zürich, Switzerland. martina.huemer@kispi.uzh.ch.
3
Department of Pediatrics, LKH Bregenz, Bregenz, Austria. martina.huemer@kispi.uzh.ch.
4
Clinic for Pediatrics I; Inherited Metabolic Disorders, Innsbruck Medical University, Innsbruck, Austria. sabine.scholl-buergi@uki.at.
5
Divisions of Nephrology and Transplantation, Geneva University Hospitals, Geneva, Switzerland. Karine.Hadaya@hcuge.ch.
6
Pediatric Nephrology & Metabolism, Children's Hospital, University of Geneva, Geneva, Switzerland. ilse.kern@hcuge.ch.
7
Department of Neurology, Innsbruck Medical University, Innsbruck, Austria. Ronny.Beer@i-med.ac.at.
8
Department of Neurology, Innsbruck Medical University, Innsbruck, Austria. Klaus.Seppi@i-med.ac.at.
9
Division of Metabolic Diseases and Children's Research Center, University Children's Hospital Zürich, Zürich, Switzerland. Brian.fowler@kispi.uzh.ch.
10
Division of Metabolic Diseases and Children's Research Center, University Children's Hospital Zürich, Zürich, Switzerland. Matthias.baumgartner@kispi.uzh.ch.
11
Radiz - Rare Disease Initiative Zürich, University Zürich, Zürich, Switzerland. Matthias.baumgartner@kispi.uzh.ch.
12
Clinic for Pediatrics I; Inherited Metabolic Disorders, Innsbruck Medical University, Innsbruck, Austria. daniela.karall@i-med.ac.at.

Abstract

BACKGROUND:

The cblC defect is a rare inborn error of intracellular cobalamin metabolism. Biochemical hallmarks are elevated homocysteine and low methionine in plasma accompanied by methylmalonic aciduria. Due to the heterogeneous clinical picture, patients with the late-onset form of the disease (onset >12 months) come to the attention of diverse medical specialists, e.g. paediatricians, neurologists, nephrologists, psychiatrists or haematologists. The report reviews the published clinical data and adds three new cases to raise awareness for this severe but often treatable disease.

METHODS:

The Pubmed and the Cochrane databases were searched for clinical reports on cblC patients and three unreported cases are presented to illustrate the clinical spectrum.

RESULTS:

Reports on 58 cases (30 females, 22 males, 6 = no information) and the three new cases underlined the clinical heterogeneity of the disease. Time between first symptoms and diagnosis ranged from three months to more than 20 years. Haemolytic uraemic syndrome and pulmonary hypertension were main presenting symptoms in preschool children. In older children/adolescents, psychiatric symptoms, cognitive impairment, ataxia and myelopathy were frequently observed while thromboembolic events and glomerulopathies were almost exclusively seen in adults. Brain atrophy, white matter lesions and myelopathy were frequently encountered. The majority of patients showed marked biochemical and clinical response to treatment with parenteral hydroxocobalamin combined with oral betaine, folate, carnitine and rarely methionine. The course was less favourable in late treated or untreated patients.

CONCLUSIONS:

The late-onset cblC defect is a rare disease and unfortunately, diagnosis is often delayed. Raising awareness for this disorder can significantly improve patients' outcome and perspective by timely initiation of targeted treatment. Newborn screening (NBS) for the cblC defect might be of benefit especially for late-onset patients since treatment seems efficient when initiated before irreversible organ damage. In general, inborn errors of metabolisms should be considered in unexplained medical cases at any age, especially in patients with multisystemic disease. More specifically, total homocysteine in plasma and methylmalonic acid in urine/plasma should be measured in unexplained neurologic, psychiatric, renal, haematologic and thromboembolic disease.

PMID:
25398587
PMCID:
PMC4255922
DOI:
10.1186/s13023-014-0161-1
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center